Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was INR 0.550847 million compared to INR 0.016949 million a year ago. Revenue was INR 1.43 million compared to INR 0.893889 million a year ago. Net loss was INR 31.58 million compared to INR 52.15 million a year ago. Basic loss per share from continuing operations was INR 0.42 compared to INR 0.69 a year ago. Diluted loss per share from continuing operations was INR 0.42 compared to INR 0.69 a year ago.